Skip to main content
. 2017 Dec 4;4(1):1409060. doi: 10.1080/20018525.2017.1409060

Figure 2.

Figure 2.

Major treatments in 2014 according to GOLD 2017 groups. Proportion of the total study population distributed over main treatment groups and GOLD ABCD groups. Bronchodilator therapy includes maintenance treatment with long- or short-acting muscarinic antagonists and/or long-acting beta-2-agonists. LABA = long-acting beta-2-agonists; ICS = inhaled corticosteroids. No/other includes patients with only rescue medication and with only ICS.